Abstract: A system including a chilled air generation system, a forced air convection system, one or more phase change material (PCM) modules, and a controller. The controller is configured to regulate the temperature of a facility by selectively utilizing the chilled air generation system and the forced air convection system based on multiple factors, which may include energy source type(s), relative costs of the energy from the source(s), availability of energy from the source(s), facility temperature, PCM module temperature, and/or temperature of goods stored within the facility, among other considerations. The controller may thus advantageously and cost-effectively control the periods of time during which the chilled air generation system is used and those during which the thermal energy stored in the PCM modules is used.

Abstract: Disclosed are methods of isolating T cells having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation, the method comprising: identifying one or more genes in the nucleic acid of a cancer cell of a patient, each gene containing a cancer-specific mutation that encodes a mutated amino acid sequence; inducing autologous APCs of the patient to present the mutated amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated amino acid sequence; and selecting the autologous T cells. Also disclosed are related methods of preparing a population of cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.

Abstract: Disclosed are methods of isolating a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation, the method comprising: identifying one or more genes in the nucleic acid of a cancer cell of a patient, each gene containing a cancer-specific mutation that encodes a mutated amino acid sequence; inducing autologous APCs of the patient to present the mutated amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated amino acid sequence; selecting the autologous T cells; and isolating a nucleotide sequence that encodes the TCR from the selected autologous T cells, wherein the TCR has antigenic specificity for the mutated amino acid sequence encoded by the cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.

Abstract: Provided herein are methods of treating B7-H1-expressing tumors comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof.

Abstract: The present invention features methods of treating lung cancer (e.g., NSCLC) with an anti-PD-L1 antibody and tremelimumab in a subject identified as having a PD-L1 negative tumor.

Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof.

Abstract: A subliner for use in a metal extrusion press, the subliner comprising an elongate annular body having an outer surface dimensioned for placement within an outer mantle, and an inner surface dimensioned to receive an inner liner. The subliner further comprises at least one heating element positioned longitudinally between the outer and inner surfaces of the elongate annular body for providing beat in at least one selected region of the subliner, in close proximity to the inner liner.

Abstract: A subliner for use in a metal extrusion press, the subliner comprising an elongate annular body having an outer surface dimensioned for placement within an outer mantle, and an inner surface dimensioned to receive an inner liner. The subliner further comprises at least one heating element positioned longitudinally between the outer and inner surfaces of the elongate annular body for providing beat in at least one selected region of the subliner, in close proximity to the inner liner.

Abstract: The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of such peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro. The method for identification of the internalizing peptides of the present invention comprises incubating a target cell with a peptide display library, isolating peptides with internalization characteristics and determining the ability of said peptide to internalize cargo into a cell.

Abstract: A subliner for use in a metal extrusion press, the subliner comprising an elongate annular body having an outer surface dimensioned for placement within an outer mantle, and an inner surface dimensioned to receive an inner liner. The subliner further comprises at least one heating element positioned longitudinally between the outer and inner surfaces of the elongate annular body for providing heat in at least one selected region of the subliner, in close proximity to the inner liner.

Abstract: The present invention relates to adenovirus-based vaccines against avian influenza viruses with pandemic potential. The present invention provides replication-defective adenoviral vectors, each having a nucleic acid encoding an influenza A polypeptide. When introduced into a subject, the expressed influenza A polypeptide induces the production of antibodies that bind to influenza. The present invention also provides methods for inducing an immune response in a subject. Subjects are administered a replication-defective adenoviral vector, wherein the vector has a nucleic acid encoding an influenza A polypeptide. When the vector is expressed in the subject, the influenza A polypeptide induces the subject to produce antibodies to influenza.

Abstract: A method and apparatus is disclosed for inspection of molded closures that would measure specific parameters of the closure on an on-line basis as they are ejected from an associated compression molding apparatus. Measuring specific parameters of the closure on an on-line basis identifies problems with specific tool sets, sub-systems, and process settings of the molding apparatus, thus substantially reducing the amount of scrap that is produced.

Abstract: The invention relates to methods of screening for binding partners, especially binding partners essential for the biological activity of erastin (e.g. VDACs such as VDAC3). The invention also provides reagents and methods for effective killing of cancer cells with erastin and related compounds or derivatives.

Abstract: The present invention relates to methods and compositions for use in mediating an immunosuppressive reaction. The compositions of the invention comprise exosomes having immunosuppressive activity. Such exosomes may be derived from a variety of different cell types, including antigen presenting cells such as dendritic cells and macrophages. Prior to isolation of exosomes, the cells may be genetically engineered to express molecules capable of enhancing the immunosuppressive activity of said exosomes and/or may be exposed to one or more agents, such as cytokines or cytokine inhibitors, which are also capable of enhancing the immunosuppressive activity of exosomes. The present invention also relates to the use of such exosomes for the treatment of diseases and disorders associated with undesirable activation of the immune system. The present invention also includes exosomes isolated directly from serum that have been shown to be immunosuppressive.

Abstract: The present invention relates to a method for treating bone pathologies comprising delivering a viral or non-viral delivery vehicle comprising genetic information (e.g. a transgene) encoding a therapeutic osteoinductive factor to target cells in vivo enabling the cells to produce the osteoinductive factor at the site of the bone pathology. The delivery is achieved by a simplified method which does not require cumbersome ex vivo techniques or additional matrix or scaffolding agents. Such viral and non-viral delivery vehicles of the present invention are derived from the following nonlimiting examples: adenoviruses, adeno-associated viruses, retroviruses, herpes simplex viruses, liposomes, and plasmids. The osteoinductive factors include, but are not limited to, growth factors, cytokines, growth factor inhibitors and cytokine inhibitors.

Abstract: A readily portable handheld security assessment device that may be manipulated for viewing the underside of objects having low ground clearance, including a high intensity light source coupled with an optical conduit adapted for uniformly illuminating the field to be viewed. A flexible ball joint assembly allows a reflector or mirror to be easily and controllably positioned and oriented under the object to facilitate visual inspection thereof while permitting the user to remain erect.

Abstract: A subliner for use in a metal extrusion press, the subliner comprising an elongate annular body having an outer surface dimensioned for placement within an outer mantle, and an inner surface dimensioned to receive an inner liner. The subliner further comprises at least one heating element positioned longitudinally between the outer and inner surfaces of the elongate annular body for providing heat in at least one selected region of the subliner, in close proximity to the inner liner.

Abstract: The present invention provides MHC Class II restricted melanoma antigens recognized by CD4+ T cells. This invention further provides prophylactic and therapeutic applications for the Class II restricted melanoma antigens. In particular, this invention provides tyrosinase Class II restricted melanoma antigens, as well as tyrosinase immunogenic peptides which have been modified to enhance their immunogenicity. These antigens can serve as an immunogens or vaccines to prevent or treat melanoma. In addition a method for isolating Class II restricted melanoma antigens or identifying new Class II restricted melanoma antigens is provided.

Abstract: The present invention provides a method for purifying a protein complex and the components comprising the complex from a cell, a cell or tissue lysate or a whole organism by employing a combined set of affinity tags of high affinity, specificity and ease of elution. The method involves using a protein or a peptide modified to contain one or more affinity tags separated by one or more specific protease cleavage sites to isolate any interacting proteins or fragments thereof. Specifically exemplified is a method employing a modified bait containing AviTag or GST and a removal tag of His6 hexapeptide positioned proximal to the bait such that any excess bait can be efficiently removed from the purified complex yielding enriched interacting proteins prior to subjecting the complex for further identification of individual components. The identification of the proteins or fragments thereof contained in the protein complex will provide new targets for the identification of new pharmaceuticals and diagnostic tools.

Abstract: The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of such peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro. The method for identification of the internalizing peptides of the present invention comprises incubating a target cell with a peptide display library, isolating peptides with internalization characteristics and determining the ability of said peptide to internalize cargo into a cell.